Published in Hepatitis Weekly, December 6th, 2004
The company said that this extension of the current label is based on the results of a study that showed combination therapy with Pegasys eradicated the virus (sustained virological response) in more than half of this patient group. Under current treatment guidelines, hepatitis C patients with normal liver enzymes would not normally be eligible for treatment.
According to the announcement, the EMEA has recognized that patients who have normal alanine...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.